MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 120 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 1.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $39,000 | -61.0% | 31,595 | -2.2% | 0.00% | – |
Q1 2017 | $100,000 | -45.7% | 32,308 | -3.5% | 0.00% | – |
Q4 2016 | $184,000 | -15.2% | 33,482 | -1.8% | 0.00% | – |
Q3 2016 | $217,000 | +197.3% | 34,087 | +154.7% | 0.00% | – |
Q2 2016 | $73,000 | -13.1% | 13,383 | +32.4% | 0.00% | – |
Q1 2016 | $84,000 | +5.0% | 10,105 | 0.0% | 0.00% | – |
Q4 2015 | $80,000 | -4.8% | 10,105 | +2.5% | 0.00% | – |
Q3 2015 | $84,000 | -11.6% | 9,859 | +28.0% | 0.00% | – |
Q2 2015 | $95,000 | +3.3% | 7,700 | 0.0% | 0.00% | – |
Q1 2015 | $92,000 | +5.7% | 7,700 | 0.0% | 0.00% | – |
Q4 2014 | $87,000 | +27.9% | 7,700 | 0.0% | 0.00% | – |
Q3 2014 | $68,000 | +15.3% | 7,700 | -5.8% | 0.00% | – |
Q2 2014 | $59,000 | +103.4% | 8,170 | +40.9% | 0.00% | – |
Q1 2014 | $29,000 | +61.1% | 5,800 | +65.7% | 0.00% | – |
Q4 2013 | $18,000 | +38.5% | 3,500 | 0.0% | 0.00% | – |
Q3 2013 | $13,000 | +85.7% | 3,500 | +250.0% | 0.00% | – |
Q2 2013 | $7,000 | – | 1,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 5,000,000 | $20,400,000 | 4.19% |
Consonance Capital Management LP | 9,067,998 | $36,997,000 | 4.06% |
Lagoda Investment Management, L.P. | 1,522,529 | $6,212,000 | 2.13% |
INDUS CAPITAL PARTNERS, LLC | 1,050,000 | $4,284,000 | 0.56% |
WESTFIELD CAPITAL MANAGEMENT CO LP | 9,072,877 | $37,017,000 | 0.32% |
GARRISON BRADFORD & ASSOCIATES INC | 77,700 | $317,000 | 0.29% |
Cannell & Co. | 1,572,978 | $6,418,000 | 0.23% |
Virtus ETF Advisers LLC | 179,625 | $733,000 | 0.22% |
LeJeune Puetz Investment Counsel LLC | 3,976 | $161,000 | 0.12% |
STONERIDGE INVESTMENT PARTNERS LLC | 221,838 | $905,000 | 0.12% |